Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System

A dysregulated immune response with hyperinflammation is observed in patients with severe coronavirus disease 2019 (COVID-19). The aim of the present study was to assess the safety and potential benefits of human recombinant C1 esterase inhibitor (conestat alfa), a complement, contact activation and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Frontiers in immunology 2020-08, Vol.11, p.2072-2072, Article 2072
Hauptverfasser:	Urwyler, Pascal, Moser, Stephan, Charitos, Panteleimon, Heijnen, Ingmar A. F. M., Rudin, Melanie, Sommer, Gregor, Giannetti, Bruno M., Bassetti, Stefano, Sendi, Parham, Trendelenburg, Marten, Osthoff, Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Betacoronavirus - drug effects C1 esterase inhibitor Complement C1 - antagonists & inhibitors Complement C1 Inhibitor Protein - analysis Complement C1 Inhibitor Protein - therapeutic use complement system Coronavirus Infections - drug therapy COVID-19 Cytokine Release Syndrome - drug therapy Factor XIa - antagonists & inhibitors Female Humans Immunology inflammation kallikrein-kinin system Kallikrein-Kinin System - drug effects Kallikreins - antagonists & inhibitors Life Sciences & Biomedicine Male Middle Aged Pandemics Pneumonia, Viral - drug therapy Recombinant Proteins - therapeutic use SARS-CoV-2 Science & Technology Viral Load - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A dysregulated immune response with hyperinflammation is observed in patients with severe coronavirus disease 2019 (COVID-19). The aim of the present study was to assess the safety and potential benefits of human recombinant C1 esterase inhibitor (conestat alfa), a complement, contact activation and kallikrein-kinin system regulator, in severe COVID-19. Patients with evidence of progressive disease after 24 h including an oxygen saturation
ISSN:	1664-3224 1664-3224
DOI:	10.3389/fimmu.2020.02072